GPX4 and diabetic kidney disease: A recent pharmacological study on fenofibrate demonstrated that restoring antioxidant capacity alleviates tubular damage and renal injury in DKD by upregulating Nrf2 expression, which in turn regulates GPX4, SLC7A11, ferritin heavy chain 1 (FTH-1), and transferrin receptor 1 (TFR-1) (39).